Current genetic models for studying congenital heart diseases: Advantages and disadvantages

Ayat Shorbaji1, Peter Natesan Pushparaj2, Sherin Bakhashab1,2

  • 1Biochemistry Department, King Abdulaziz University, Jeddah, Saudi Arabia.

Bioinformation
|August 12, 2024
PubMed

Insights

This review evaluates various animal and stem cell models for studying congenital heart disease (CHD). Understanding these models aids in comprehending CHD pathology and developing effective therapies.

Area of Science:

  • Cardiovascular Research
  • Developmental Biology
  • Genetics

Background:

  • Congenital heart disease (CHD) involves structural and functional heart anomalies, with increasing global prevalence due to improved diagnostics.
  • Numerous CHD-related genes have been identified, offering insights into molecular mechanisms.
  • Understanding CHD requires effective research models.

Purpose of the Study:

  • To review and compare the advantages and challenges of diverse in vitro and in vivo models for congenital heart disease research.
  • To assess the suitability of various models, including primates, canines, Xenopus, rabbits, chicks, mice, Drosophila, zebrafish, and induced pluripotent stem cells (iPSCs), for studying CHD.
  • To guide the selection of appropriate models based on specific research objectives.

Main Methods:

  • Comparative analysis of in vitro and in vivo models for congenital heart disease (CHD).
  • Evaluation of biological characteristics, disease vulnerability, induction methods, and human comparability of models.
  • Inclusion of primates, canines, Xenopus frogs, rabbits, chicks, mice, Drosophila, zebrafish, and induced pluripotent stem cells (iPSCs).

Main Results:

  • Each model (primates, canines, Xenopus, rabbits, chicks, mice, Drosophila, zebrafish, iPSCs) presents unique advantages and limitations regarding cost, genetic manipulation, physiological similarity, and technical feasibility.
  • Zebrafish offer high gene conservation and cardiac similarity but face antibody cross-reactivity issues.
  • iPSCs show potential for gene editing but have structural and stability challenges.

Conclusions:

  • Diverse CHD models provide valuable insights into cardiac development, disease simulation, and genetic factor verification.
  • Model selection depends on research goals, impacting the understanding of CHD pathology and therapy development.
  • Further research utilizing these models is crucial for advancing CHD treatment strategies.